💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Pantoprazole

CHEMBL1502 Phase 4 Approuvé Small molecule
Half-Life
1 hour
Bioavailability
—
Protein Binding
—
Molecular Weight
383.4 g/mol
LogP
2.4
Phase
4

This proton pump inhibitor reduces stomach acid production to treat acid reflux, ulcers, and esophageal damage.

Masse moléculaire

383,3710 g/mol

LogP

2,40

TPSA

106,00 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pancreatic Cancer Pain Management Non-Small Cell Lung Cancer Migraine Schizophrenia Oncology Gastroesophageal Reflux Disease Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Obesity Type 2 Diabetes Hypertension Breast Cancer Atopic Dermatitis Chronic Pain Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer

Classes de médicaments

A — A - Alimentary Tract and Metabolism

Mécanisme d'action

Proton pump inhibitor.

Pharmacokinetics (PK)

Half-Life 1 hour

Pharmacodynamics (PD)

Mécanisme

Proton pump inhibitor.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC

                

                

                
                

                    
InChI

                    
InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H15F2N3O4S

                    

                    
                    

                        
HBD / HBA

                        
1 / 9

                    

                    
                    

                        
Liaisons Rotatives

                        
7

                    

                    
                    
                    

                        
Atomes Lourds

                        
26

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            ATP4A (Proton Pump (H+/K+-ATPase))
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Pantoprazole + Clopidogrel
                            
                        

                        
                        
Pantoprazole has minimal CYP2C19 inhibitory activity compared with omeprazole, making it the preferred PPI choice in patients on clopidogrel.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Pantoprazole + Levothyroxine
                            
                        

                        
                        
Like all PPIs, pantoprazole reduces gastric acid and impairs levothyroxine tablet dissolution, leading to decreased T4 absorption and potentially under-treated hypothyroidism.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
This proton pump inhibitor reduces stomach acid production to treat acid reflux, ulcers, and esophageal damage.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Proton pump inhibitor.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Pantoprazole: Half-life: 1 hour.

                        

                    

                    

                    

                        
                        

                            
Yes, Pantoprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Metformin
                            Small molecule
                        
                        
                        
                            Omeprazole
                            Small molecule
                        
                        
                        
                            Lansoprazole
                            Small molecule
                        
                        
                        
                            Insulin Glargine
                            Protein
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1502.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4679.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.